HIV drugmakers ViiV, Gilead top 2018 pharma reputation survey

ReputationSign
Viiv, Gilead and Janssen led among global pharma companies in PatientView's annual reputation survey of patient groups. (Alpha Stock Images)

Pharma’s reputation is holding steady. That’s according to the annual patient group opinion report from PatientView, which found that 41% thought the pharma industry reputation's was “excellent” or “good” in 2018, compared with a similar 43% in 2017.

Fifty-three percent of patient groups also rated the industry as excellent or good for the making of high-quality products. That’s down a bit from 57% in the 2017 survey.

Among individual pharma company ratings, GlaxoSmithKline's HIV arm, ViiV Healthcare, continued as No. 1 again in 2018 among the 46 companies ranked. Alex Wyke, PatientView CEO, said ViiV has “done an excellent job” working with patient groups in HIV and AIDS and listening to patients’ needs and wants, as well as providing funding for groups.

FierceBiotech Executive Breakfast

Getting Real: The Changing Tide on Real-World Evidence in Drug Development

Join FierceBiotech and a panel of industry experts for an executive breakfast at BIO. We will discuss the impacts of real-world evidence on drug development and address the important questions that companies are facing including where to find the right talent & technology and how to deploy it internally or with partners. Join us in Philadelphia on June 5th for this important discussion.

RELATED: Skepticism on the wane? Reputation study says U.S. patient groups give props to pharma

Its rival HIV drugmaker, Gilead Sciences, ranked No. 2, up one spot from the previous year. But as Wyke noted, Gilead was also up from a few years back, when patient groups turned against the company over its high-priced hepatitis C drugs. It seems to suggest “an end to the hostility” from patient groups, she said.

In third place was Johnson & Johnson pharma unit Janssen, which moved up from fifth place last year. Janssen’s high placement is impressive, Wyke said, because of its broad portfolio of drugs and therefore broader exposure to patient groups. Unlike ViiV, for instance, which only works in HIV, Janssen has to appease and appeal to patient groups across many different therapy areas.

Janssen wrote about its concerted effort to include patients as research partners in 2018 in an answer to PatientView questions, noting, in part: “We are systematically incorporating patient perspectives into Research and Development and clinical-trial design, to develop medicines that better meet needs, and are available to patients faster. In 2018, all high-priority Janssen medicines in development had a Patient Voice Plan. This means that patients were consulted, and served as research partners.”

One ongoing issue across all pharma company brands is transparency and pricing. While Wyke said that while it seems as though the Trump phenomenon—putting pharma companies front and center to blame for high pricing—has waned somewhat globally, the concern from patient groups has not. Overall, only 9% of patient groups rated the industry as “excellent” or “good” on fair pricing policies.

RELATED: Trust pharma? Not so much, annual survey shows, with biggest loss ever

“Clearly, pricing and transparency remain a huge problem,” Wyke said, adding that “only 30% out of the whole sample were even willing to nominate a company that they thought were good or best at transparency and pricing, even though nearly every group has relationships with pharma companies.”

Among the biggest movers in the survey, Takeda made the “almost unprecedented leap” of going from No. 37 last year way up to No. 7, which PatientView attributed to its acquisition of Shire as well as more recent concerted efforts to improve patient centricity. Another mover was Sanofi, which jumped up five places to No. 10 in the 2018 survey.

Suggested Articles

Celltrion Chairman Seo Jung-jin says the South Korean company will spend about $33 billion over a decade on its biologics and pharma businesses.

Purdue took a big hit when it settled with Oklahoma over claims it misleadingly advertised its powerful opioid, OxyContin. Now more states want in.

The new endorsement of Celgene's Revlimid from England's cost watchdog NICE may not help calm fears about BMS' $74 billion buyout.